内乳及内侧锁骨上淋巴结放疗技术与临床结局的关联:EORTC 22922/10925随机试验结果
该多中心随机试验1996至2004年纳入4004例I-III期乳腺癌患者,比较内乳及内侧锁骨上淋巴结照射与不放疗对生存和死因的影响,中位随访15.7年。本分析按三种放疗技术分组探索性描述结局,个体化技术组无病生存、总生存和乳腺癌特异性死亡的绝对改善分别为6.8%、4.9%和-5.8%,标准技术组分别为-1.4%、1.1%和-3%,各技术组副作用增加相似。
要点
- 个体化技术组内乳及内侧锁骨上放疗较不放疗的无病生存绝对改善6.8%,标准技术组为-1.4%。
- 个体化技术组总生存绝对改善4.9%,标准改良技术组2.9%,标准技术组1.1%。
- 各技术组因内乳及内侧锁骨上放疗增加的15年副作用率相似。
核心结论
- 尽管因机构间基线特征差异无法按技术直接比较,研究结果提示使用更个体化的放疗技术与更高的肿瘤学改善率相关,且未增加晚期副作用风险。
研究设计与样本
- 多中心EORTC 22922/10925随机试验(NCT00002851)于1996年至2004年开展,评估I-III期乳腺癌患者内乳及内侧锁骨上淋巴结链照射与不再放疗对生存和死因的影响。
- 13个国家46个放射肿瘤科共纳入4004例患者,中位随访15.7年;按三种内乳及内侧锁骨上放疗技术分组进行探索性描述分析,技术在各机构试验期间固定。
主要发现
- 各技术组患者数:标准技术2440例(61%),标准改良技术635例(16%),个体化技术929例(23%)。
- 内乳及内侧锁骨上放疗较不放疗的无病生存绝对改善:个体化技术组6.8%,标准改良技术组1.6%,标准技术组-1.4%。
- 内乳及内侧锁骨上放疗较不放疗的总生存绝对改善:个体化技术组4.9%,标准改良技术组2.9%,标准技术组1.1%。
- 内乳及内侧锁骨上放疗较不放疗的乳腺癌特异性死亡绝对改善:个体化技术组-5.8%,标准改良技术组-4.3%,标准技术组-3%。
- 因内乳及内侧锁骨上放疗增加的15年副作用率(纵向和横断面评分)在各技术组间相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因机构间基线特征存在差异,无法按放疗技术进行直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The multicentre EORTC 22922/10925 trial (ClinicalTrials.gov, NCT00002851) was conducted between 1996 and 2004. The trial evaluated the effect of irradiation of the internal mammary and medial supraclavicular lymph node chains (IM-MS) vs no further radiation therapy (RT) on survival and cause of death in breast cancer stage I-III patients. At 15.7 years of median follow-up, a significant reduction of breast cancer specific mortality (BCSM) and any recurrence, not translating in improved overall survival (OS), and low absolute rates of side effects were found. The aim of the current analysis was to evaluate the association of RT techniques of IM-MS lymph node irradiation with long-term outcomes. PATIENTS AND METHODS: Three RT techniques were used for IM-MS: a standard technique using a fixed set-up combining photon/electron beams to the IM and tangential fields to the breast or chest wall vs a standard-modified technique with minor adaptation for beam settings vs a more individualised technique based on individual localisation of the IM. Techniques used were fixed per institution over the duration of the trial. We performed an exploratory and descriptive analysis of the outcomes after 15 years follow-up for the three RT techniques. RESULTS: Between July 1996 and January 2004, 46 radiation oncology departments from 13 countries accrued 4004 patients. Median follow-up was 15.7 years. The number of patients treated by each technique was 2440 (61%) by standard vs 635 (16%) by standard-modified vs 929 (23%) patients by individualised technique. The absolute improvements of oncological outcomes in terms of disease-free survival (DFS), OS and BCSM with IM-MS RT compared to no IM-MS RT were 6.8%, 4.9% and -5.8% for the individualised technique, vs 1.6%, 2.9% and -4.3% for modified standard and -1.4%, 1.1% and -3% for standard technique, respectively. The increase in 15-year rates of side effects due to IM-MS RT, both scored longitudinally and cross-sectionally, were similar among the techniques. CONCLUSION: Even though a straightforward comparison by technique is not possible because of variations in baseline characteristics between institutions, our findings suggest that the use of more individualised RT techniques is associated with higher rates of oncological improvements without increased risks for late side effects.
引用
- Kaidar-Person O, Fortpied C, Hol S, et al. The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: Results from the EORTC 22922/10925 randomised trial. Radiother Oncol. 2022. PMID: 35568284. doi:10.1016/j.radonc.2022.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。